This new indication for Orencia provides significant evidence of its durable efficacy and long-term safety in pediatric patients, including those initiating biologic therapy for the first time. The safety and efficacy of Orencia in juvenile idiopathic arthritis (JIA) were assessed in a three-part study through one year.
Elliott Sigal, executive vice president, chief scientific officer and president, R&D, Bristol-Myers Squibb, said: “Juvenile idiopathic arthritis is the most prevalent form of arthritis in children. This new indication for Orencia offers another treatment option to help improve signs and symptoms of this serious disease in pediatric and adolescent patients.”